Paolo Anderlini, Rima M Saliba, Celina Ledesma, Tamera Plair, Amin M Alousi, Chitra M Hosing, Issa F Khouri, Yago Nieto, Uday R Popat, Elizabeth J Shpall, Michelle A Fanale, Frederick B Hagemeister, Yasuhiro Oki, Saatva Neelapu, Jorge E Romaguera, Anas Younes, Richard E Champlin
Forty patients (median age, 31 years; range, 20 to 63) with Hodgkin lymphoma underwent an allogeneic stem cell transplant with the gemcitabine-fludarabine-melphalan reduced-intensity conditioning regimen. Thirty-one patients (77%) had undergone a prior autologous stem cell transplant, with a median time to progression after transplant of 6 months (range, 1 to 68). Disease status at transplant was complete remission/complete remission, undetermined (n = 23; 57%), partial remission (n = 14; 35%), and other (n = 3; 8%)...
July 2016: Biology of Blood and Marrow Transplantation